# Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus

> **NCT07253688** · PHASE3 · RECRUITING · sponsor: **Todd C. Lee MD MPH FIDSA** · enrollment: 330 (estimated)

## Conditions studied

- Staphylococcus Aureus Endocarditis
- Prosthetic Valve Endocarditis

## Interventions

- **DRUG:** Rifampin
- **OTHER:** No rifampin

## Key facts

- **NCT ID:** NCT07253688
- **Lead sponsor:** Todd C. Lee MD MPH FIDSA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-10
- **Primary completion:** 2029-12
- **Final completion:** 2030-07
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253688, "Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT07253688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*